4D Molecular Insider Sale: Routine Liquidity Move, No Confidence Drop
David Kirn’s September 14 sale of 58,333 4D Molecular Therapeutics shares is a routine, rule‑based liquidity move, not a warning sign—investors should watch future trades to gauge confidence.
- 4D MOLECULAR THERAPEUTICS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read